PL2544682T3 - Fitokannabinoidy w leczeniu glejaka - Google Patents
Fitokannabinoidy w leczeniu glejakaInfo
- Publication number
- PL2544682T3 PL2544682T3 PL11709175T PL11709175T PL2544682T3 PL 2544682 T3 PL2544682 T3 PL 2544682T3 PL 11709175 T PL11709175 T PL 11709175T PL 11709175 T PL11709175 T PL 11709175T PL 2544682 T3 PL2544682 T3 PL 2544682T3
- Authority
- PL
- Poland
- Prior art keywords
- phytocannabinoids
- glioblastoma
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1004137.4A GB2478595B (en) | 2010-03-12 | 2010-03-12 | Phytocannabinoids in the treatment of glioma |
| EP11709175.1A EP2544682B1 (en) | 2010-03-12 | 2011-03-11 | Phytocannabinoids in the treatment of cancer |
| PCT/GB2011/050487 WO2011110866A1 (en) | 2010-03-12 | 2011-03-11 | Phytocannabinoids in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2544682T3 true PL2544682T3 (pl) | 2016-08-31 |
Family
ID=42261478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11709175T PL2544682T3 (pl) | 2010-03-12 | 2011-03-11 | Fitokannabinoidy w leczeniu glejaka |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8790719B2 (pl) |
| EP (1) | EP2544682B1 (pl) |
| JP (1) | JP5785569B2 (pl) |
| KR (1) | KR20130067248A (pl) |
| CN (1) | CN102869356A (pl) |
| AR (1) | AR080454A1 (pl) |
| AU (3) | AU2011225837A1 (pl) |
| BR (1) | BR112012023017A8 (pl) |
| CA (1) | CA2792722A1 (pl) |
| CO (1) | CO6630103A2 (pl) |
| CY (1) | CY1117451T1 (pl) |
| DK (1) | DK2544682T3 (pl) |
| EA (1) | EA201290901A1 (pl) |
| ES (1) | ES2569669T3 (pl) |
| GB (1) | GB2478595B (pl) |
| HR (1) | HRP20160427T1 (pl) |
| HU (1) | HUE029817T2 (pl) |
| IL (1) | IL221871A (pl) |
| MX (1) | MX2012010512A (pl) |
| NZ (2) | NZ602953A (pl) |
| PH (1) | PH12012501782A1 (pl) |
| PL (1) | PL2544682T3 (pl) |
| SG (1) | SG184016A1 (pl) |
| SI (1) | SI2544682T1 (pl) |
| TW (1) | TWI461205B (pl) |
| UA (1) | UA109271C2 (pl) |
| WO (1) | WO2011110866A1 (pl) |
| ZA (1) | ZA201207574B (pl) |
Families Citing this family (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2377218A (en) * | 2001-05-04 | 2003-01-08 | Gw Pharmaceuticals Ltd | Process and apparatus for extraction of active substances and enriched extracts from natural products |
| CA2586358C (en) | 2004-11-16 | 2015-11-24 | Gw Pharma Limited | Use of tetrahydrocannabivarin (thcv) as neutral antagonist of the cb1 cannabinoid receptor |
| GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| GB2460672B (en) * | 2008-06-04 | 2012-01-04 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents |
| GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2494461A (en) * | 2011-09-12 | 2013-03-13 | Gw Pharma Ltd | Phytocannabinoids for use in the treatment of invasive cancers or metastases |
| GB2514054A (en) * | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB201117956D0 (en) * | 2011-10-18 | 2011-11-30 | Otsuka Pharma Co Ltd | Phytocannabinoids for use in the treatment of breast cancer |
| WO2013164824A1 (en) | 2012-05-03 | 2013-11-07 | Magdent Ltd. | Bone enhancement device and method |
| US20150313868A1 (en) | 2012-12-18 | 2015-11-05 | Kotzker Consulting Llc | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity |
| JP6581509B2 (ja) | 2013-02-28 | 2019-09-25 | ティーウィノット テクノロジーズ リミテッド | 化合物を合成する化学工学プロセス及び装置 |
| EP2968259B1 (en) | 2013-03-14 | 2022-09-14 | SC Laboratories Inc. | Bioactive concentrates and uses thereof |
| MX384420B (es) | 2013-03-15 | 2025-03-14 | Biotech Inst Llc | Cultivo, producción, procesamiento y uso de cannabis de especialidad. |
| US10441617B2 (en) | 2013-03-15 | 2019-10-15 | Biotech Institute, Llc | Breeding, production, processing and use of medical cannabis |
| GB2513167B (en) * | 2013-04-18 | 2016-03-02 | Otsuka Pharma Co Ltd | Tetrahydrocannabivarin for use in the treatment of nausea and vomiting |
| GB2516814B (en) * | 2013-06-19 | 2016-08-31 | Otsuka Pharma Co Ltd | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer |
| GB2515312A (en) * | 2013-06-19 | 2014-12-24 | Gw Pharma Ltd | The use of phytocannabinoids in the treatment of ovarian carcinoma |
| US10774288B2 (en) | 2013-09-18 | 2020-09-15 | The Werc Shop, LLC | Terpene-based compositions, processes, methodologies for creation and products thereby |
| WO2015068052A2 (en) * | 2013-10-31 | 2015-05-14 | Full Spectrum Laboratories, Ltd. | Terpene and cannabinoid formulations |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| GB2527590A (en) * | 2014-06-27 | 2015-12-30 | Otsuka Pharma Co Ltd | Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer |
| AU2015292915B2 (en) | 2014-07-21 | 2020-10-15 | Pharmaceutical Productions, Inc. | Solid dosage form composition for buccal or sublingual administration of cannabinoids |
| WO2016030828A1 (en) | 2014-08-25 | 2016-03-03 | Full Spectrum Laboratories Limited | Apparatus and methods for the simultaneous production of cannabinoid compounds |
| EP3193862B1 (en) | 2014-09-16 | 2023-10-18 | Igc Pharma Ip, Llc | Topical cannabinoid composition for treating arthritic pain |
| US9844518B2 (en) | 2014-09-30 | 2017-12-19 | MJAR Holdings, LLC | Methods of growing cannabaceae plants using artificial lighting |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| EP3209312A1 (en) * | 2014-10-21 | 2017-08-30 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
| CN104277917B (zh) * | 2014-10-24 | 2018-02-09 | 汉康(云南)生物科技有限公司 | 一种富含大麻二酚的工业大麻精油提取方法及其提取设备 |
| WO2016105514A1 (en) | 2014-12-23 | 2016-06-30 | Biotech Institute, Llc | A reliable and robust method for the analysis of cannabinoids and terpenes in cannabis |
| US10751300B2 (en) | 2015-01-25 | 2020-08-25 | India Globalization Capital, Inc. | Composition and method for treating seizure disorders |
| WO2016123160A1 (en) | 2015-01-26 | 2016-08-04 | Biotech Institute, Llc | Systems, apparatuses, and methods for classification |
| US10238745B2 (en) | 2015-01-31 | 2019-03-26 | Constance Therapeutics, Inc. | Cannabinoid composition and products including α-tocopherol |
| MX386351B (es) | 2015-01-31 | 2025-03-18 | Constance Therapeutics Inc | Métodos para la preparación de extractos y composiciones de aceite de cannabis. |
| AU2016225026A1 (en) * | 2015-02-27 | 2017-09-07 | Canopy Growth Corporation | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
| EP3261629A4 (en) * | 2015-02-27 | 2018-12-05 | Ebbu, LLC | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
| US12303541B2 (en) | 2015-04-01 | 2025-05-20 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Erodium crassifolium L'Her plant extracts and uses thereof |
| US10960035B2 (en) | 2015-04-01 | 2021-03-30 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Voleaui Center) | Erodium crassifolium L'Her plant extracts and uses thereof |
| CN107735086A (zh) * | 2015-05-07 | 2018-02-23 | 马克·安德鲁·夏尔多内 | 大麻油的氢化 |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US11369655B2 (en) | 2015-07-06 | 2022-06-28 | Cg-Bio Genomics, Inc. | Healthful supplements |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| US10596159B2 (en) | 2015-08-12 | 2020-03-24 | India Globalization Capital, Inc. | Method and composition for treating cachexia and eating disorders |
| CA3006182A1 (en) * | 2015-11-24 | 2017-06-01 | Constance Therapeutics, Inc. | Cannabis oil compositions and methods for preparation thereof |
| BR112018068986B1 (pt) * | 2016-03-18 | 2023-03-21 | Christopher Brian Reid | Composição para reduzir a expressão oncógena de uma célula, tecido ou órgão de um indivíduo |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
| CA3027862A1 (en) | 2016-06-15 | 2017-12-21 | India Globalization Capital, Inc. | Method and composition for treating seizure disorders |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| MX386620B (es) * | 2016-08-03 | 2025-03-19 | Zelda Therapeutics Operations Pty Ltd | Composicion de cannabis |
| JP2019526541A (ja) | 2016-08-03 | 2019-09-19 | ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド | 大麻組成物 |
| JP2019523282A (ja) * | 2016-08-03 | 2019-08-22 | ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド | 大麻組成物 |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| US10568865B2 (en) | 2016-08-29 | 2020-02-25 | Canopy Growth Corporation | Water soluble compositions comprising purified cannabinoids |
| US12485129B2 (en) | 2016-08-29 | 2025-12-02 | Canopy Growth Corporation | Water soluble compositions comprising purified cannabinoids |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| CA3054690A1 (en) * | 2017-03-01 | 2018-09-07 | Canopy Growth Corporation | Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes |
| WO2018163164A1 (en) * | 2017-03-05 | 2018-09-13 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Compositions and methods for treating cancer |
| WO2018205038A1 (en) * | 2017-05-12 | 2018-11-15 | Tetra Bio-Pharma Inc. | Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling |
| JP2020520966A (ja) * | 2017-05-22 | 2020-07-16 | ジービーエス グローバル バイオファーマ，インコーポレイテッド | Ｔｒｐｖ１を標的にするミルセン及びカンナビノイド含有組成物 |
| EP3641754A4 (en) | 2017-06-19 | 2021-03-10 | Zelda Therapeutics Operations Pty Ltd | COMPOSITIONS AND TREATMENTS AGAINST SLEEP DISORDERS |
| CN111032088A (zh) | 2017-06-20 | 2020-04-17 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 大麻二酚酸酯类组合物及其用途 |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| EP3644976A4 (en) * | 2017-06-28 | 2021-03-24 | Buzzelet Development And Technologies Ltd | TERPEN-ENRICHED CANNABINOID PRODUCT FOR WOMEN'S HEALTH |
| US20200352901A1 (en) * | 2017-09-02 | 2020-11-12 | Scientific Holdings, Llc | Tetrahydrocannabinol modulators |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| CN108204786A (zh) * | 2018-01-15 | 2018-06-26 | 武汉盛硕电子有限公司 | 一种基于手机模块的北斗测量系统 |
| US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
| WO2019144126A1 (en) * | 2018-01-22 | 2019-07-25 | Pascal Biosciences Inc. | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
| CN119868317A (zh) | 2018-02-08 | 2025-04-25 | 南加州大学 | 穿透血脑屏障的方法 |
| KR20190098649A (ko) | 2018-02-14 | 2019-08-22 | (주)카이언바이오텍 | 칸나비디올 추출물을 함유하는 대장암 예방 또는 치료용 약학 조성물 |
| KR102041875B1 (ko) | 2018-02-14 | 2019-11-08 | (주)카이언바이오텍 | 대마로부터 추출된 칸나비디올 추출물 및 트레일을 함유하는 대장암 예방 또는 치료용 약학 조성물 |
| CN113264914A (zh) * | 2018-02-20 | 2021-08-17 | 麦姆德制药(佛罗里达)公司 | 用于治疗物质成瘾和其它障碍的遗传修饰的大麻植物和修饰的大麻素化合物 |
| CA3095729A1 (en) | 2018-03-30 | 2019-10-03 | India Globalization Capital, Inc. | Method and composition for treating cns disorders |
| US11607423B2 (en) | 2018-04-04 | 2023-03-21 | Akos Biosciences, Inc. | Combination of a cannabinoid and a chemotheraopeutic agent for the treatment of breast cancer |
| SG11202010006UA (en) | 2018-04-09 | 2020-11-27 | Ellevet Sciences | Hemp extract for treatment of pain in animals |
| WO2019227167A1 (en) * | 2018-06-01 | 2019-12-05 | The University Of Sydney | Compositions and treatments |
| WO2020012315A1 (en) | 2018-07-08 | 2020-01-16 | Buzzelet Development And Technologies Ltd. | Terpene-enriched cannabinoid composition for treatment of male subjects |
| EP3666765A1 (en) * | 2018-12-11 | 2020-06-17 | Emerald Health Biotechnology España,S.L.U. | Chromenic phytocannabinoids, their synthesis and use in treatment or prevention of disease |
| US20220040144A1 (en) * | 2018-12-12 | 2022-02-10 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization | Compositions and methods for the treatment of cutaneous t cell lymphoma (ctcl) |
| EP3917904A4 (en) * | 2019-01-31 | 2022-11-16 | Cava Healthcare Inc. | COMPOUNDS TO INCREASE MHC-I EXPRESSION AND MODULATE HISTONE DEACETYLASE ACTIVITY |
| NL2022614B1 (en) * | 2019-02-21 | 2020-08-31 | Patrick Alexander Unger | Pharmaceutical, phyto-cannabinoid based compositions |
| CN118831076A (zh) | 2019-03-12 | 2024-10-25 | Epm (Ip)公司 | 大麻素酸酯组合物及其用途 |
| WO2020206132A1 (en) * | 2019-04-02 | 2020-10-08 | Ulagaraj Selvaraj | Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening and immediate drug release following intravenous administration |
| US12178797B2 (en) | 2019-05-03 | 2024-12-31 | Zyus Life Sciences Inc. | Formulation for pain management |
| ES2986503T3 (es) | 2019-05-03 | 2024-11-11 | Zyus Life Sciences Inc | Formulación para el manejo del dolor que comprende tetrahidrocannabinol (THC), cannabicromeno (CBC) y cannabidiol (CBD) en una proporción determinada |
| US12220396B2 (en) | 2019-05-03 | 2025-02-11 | Zyus Life Sciences Inc. | Formulation for pain management |
| CA3140290A1 (en) | 2019-05-16 | 2020-11-19 | Technion Research & Development Foundation Limited | Cannabinoids and uses thereof |
| GB201910389D0 (en) | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
| GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| CN111184710A (zh) * | 2020-03-02 | 2020-05-22 | 福建省中科生物股份有限公司 | 一种环酚的应用和制备方法 |
| CA3175684A1 (en) | 2020-04-29 | 2021-11-04 | Jon Penarando Saez | Cannabinoids for use in supressing cancer stem cells |
| EP3912485A1 (en) | 2020-05-18 | 2021-11-24 | Del-Vis Sp. z o.o. | Cigarette product and a method for manufacturing the product |
| CN111773390B (zh) * | 2020-07-01 | 2021-08-20 | 南京大学 | 一种药物在制备治疗脑转移瘤及其相关疾病的药品中的应用 |
| GB2597321A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| US20230248745A1 (en) * | 2020-07-22 | 2023-08-10 | The University Of British Columbia | Silver enhanced cannabinoid antibiotics |
| WO2022043961A1 (en) * | 2020-08-31 | 2022-03-03 | Nelson Mandela University | Cannabinoid combinations and their use in the treatment of cancer |
| GB202013765D0 (en) | 2020-09-02 | 2020-10-14 | Gw Res Ltd | Method of preparing cannabinoids |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| EP4259122A4 (en) * | 2020-12-08 | 2025-01-15 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Institute) | Compositions and methods for the treatment of urothelial cancer |
| GB2602019A (en) | 2020-12-15 | 2022-06-22 | Gw Res Ltd | Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof |
| EP4281046B1 (en) * | 2021-01-25 | 2025-09-10 | LDN Pharma Limited | Naltrexone compositions |
| IL307444A (en) * | 2021-04-05 | 2023-12-01 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo | Preparations and methods for the treatment of cancer |
| WO2022232574A1 (en) | 2021-04-29 | 2022-11-03 | Tilray, Inc. | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| JP2024540038A (ja) | 2021-10-26 | 2024-10-31 | エコファイバー ユーエスエイ インコーポレイテッド | 麻抽出物で卵巣がんを治療する方法 |
| KR20240122436A (ko) | 2021-10-26 | 2024-08-12 | 에코파이버 유에스에이 인코포레이티드 | 대마 추출물을 생성하기 위한 시스템 및 방법과 조성물 |
| US11654172B2 (en) | 2021-10-26 | 2023-05-23 | Ecofibre Limited | Methods of treating endometriosis and other non-cancer gynecological disorders with hemp extract |
| WO2023130161A1 (en) * | 2022-01-10 | 2023-07-13 | Dolce Cann Global Pty Ltd | Compositions and methods for treating non-neurological disorders with combination products comprising a cannabinoid mixture rich in cannabidiolic acid (cbda) along with an additional active agent |
| WO2023130160A1 (en) * | 2022-01-10 | 2023-07-13 | Dolce Cann Global Pty Ltd | Compositions and methods for treating non-neurological disorders with combination products comprising a cannabinoid mixture rich in cannabidiolic acid (cbda). |
| US12440454B2 (en) | 2022-02-01 | 2025-10-14 | Portland Technology Holdings Llc | Pharmaceutical compositions containing hemp extract for administration to felines and related methods |
| WO2023161921A2 (en) * | 2022-02-23 | 2023-08-31 | Cannabotech Ltd. | Compositions for use as an adjunctive therapy in the treatment of breast cancer |
| WO2023238114A1 (en) * | 2022-06-08 | 2023-12-14 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) | Combinations and methods for the treatment of cancer |
| WO2023239415A1 (en) * | 2022-06-08 | 2023-12-14 | Angrow Company Limited | Compositions including cannabinoid and use thereof in the manufacture of a medicament for the treatment of inflammation in a subject |
| EP4568702A1 (en) | 2022-08-12 | 2025-06-18 | Jazz Pharmaceuticals Research UK Limited | Oral solid dosage forms comprising cannabinoids |
| WO2024082014A1 (en) * | 2022-10-21 | 2024-04-25 | Dolce Cann Global Pty Ltd | Compositions comprising cannabidiolic acid and fatty acids |
| IL320518A (en) | 2022-10-26 | 2025-06-01 | Ecofibre Usa Inc | Stabilized compositions containing cannabidiol |
| EP4608425A1 (en) | 2022-10-26 | 2025-09-03 | Ecofibre USA Inc. | Methods of treating estrogen sensitive diseases with cannabis extract |
| CN115583933B (zh) * | 2022-10-31 | 2024-02-06 | 暨明医药科技（苏州）有限公司 | 一种高纯度四氢大麻素同系物的制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2238707A (en) | 1989-12-08 | 1991-06-12 | Peter Bullock | Repairing footwear |
| US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
| ES2164584A1 (es) | 2000-02-11 | 2002-02-16 | Univ Madrid Complutense | Terapia con cannabinoides para el tratamiento de tumores cerebrales. |
| US20040039048A1 (en) | 2000-02-11 | 2004-02-26 | Manuel Guzman Pastor | Therapy with cannabinoid compounds for the treatment of brain tumors |
| ES1045342Y (es) | 2000-02-11 | 2001-02-16 | Alvarez Manuel Couto | Expositor giratorio para postales, fotos y similares. |
| US6448288B1 (en) | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
| AU2001290949A1 (en) | 2000-09-14 | 2002-03-26 | California Pacific Medical Center | Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma |
| DE10051427C1 (de) * | 2000-10-17 | 2002-06-13 | Adam Mueller | Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte |
| US7025992B2 (en) | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
| GB2380129B (en) | 2001-02-14 | 2004-08-11 | Gw Pharma Ltd | Pharmaceutical formulations |
| CH695661A5 (de) | 2001-03-06 | 2006-07-31 | Forsch Hiscia Ver Fuer Krebsfo | Pharmazeutische Zusammensetzung. |
| EP1482917B1 (en) * | 2002-02-01 | 2019-05-08 | GW Pharma Limited | Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions |
| GB0202385D0 (en) * | 2002-02-01 | 2002-03-20 | Gw Pharma Ltd | Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions |
| US20080057117A1 (en) | 2002-02-15 | 2008-03-06 | Forschungs Institut Miscia Verenfur Krebsforschung | Pharmaceutical composition made up of cannibus extracts |
| IL148244A0 (en) | 2002-02-19 | 2002-09-12 | Yissum Res Dev Co | Anti-nausea and anti-vomiting activity of cannabidiol compounds |
| CA2483072A1 (en) | 2002-04-25 | 2003-11-06 | Virginia Commonwealth University | Cannabinoids |
| GB2391865B (en) | 2002-08-14 | 2005-06-01 | Gw Pharma Ltd | Improvements in the extraction of pharmaceutically active components from plant materials |
| US6946150B2 (en) * | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
| GB2394894B (en) | 2002-11-04 | 2005-08-31 | G W Pharma Ltd | New use for pharmaceutical composition |
| GB2414933B (en) | 2004-06-08 | 2009-07-15 | Gw Pharma Ltd | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis |
| GB2418612A (en) | 2004-10-01 | 2006-04-05 | Gw Pharma Ltd | Inhibition of tumour cell migration with cannabinoids |
| WO2006107903A2 (en) | 2005-04-01 | 2006-10-12 | Intezyne Technologies, Incorporated | Polymeric micelles for drug delivery |
| US7968594B2 (en) | 2005-04-27 | 2011-06-28 | Gw Pharma Limited | Pharmaceutical compositions for the treatment of pain |
| AU2006247526A1 (en) | 2005-05-13 | 2006-11-23 | Unimed Pharmaceuticals, Inc. | Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting |
| GB2434312B (en) * | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
| GB2438682A (en) * | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
| GB2439393B (en) | 2006-06-23 | 2011-05-11 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
| US20080103193A1 (en) * | 2006-10-26 | 2008-05-01 | Trevor Percival Castor | Methods for making compositions and compositions for treating pain and cachexia |
| JP2010520269A (ja) * | 2007-03-05 | 2010-06-10 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム | カンナビノイドの新規キノノイド誘導体及び悪性腫瘍の治療におけるそれらの使用 |
| GB2448535A (en) * | 2007-04-19 | 2008-10-22 | Gw Pharma Ltd | New use for cannabinoid-containing plant extracts |
| US9084771B2 (en) | 2007-05-17 | 2015-07-21 | Sutter West Bay Hospitals | Methods and compositions for treating cancer |
| GB2449691A (en) * | 2007-05-31 | 2008-12-03 | Gw Pharma Ltd | A reference plant lacking medicinal active compound expression |
| GB2450741A (en) * | 2007-07-05 | 2009-01-07 | Gw Pharma Ltd | Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease |
| EP2044935B1 (en) * | 2007-10-02 | 2011-01-05 | Vivacell Biotechnology Espana S.L. | A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases |
| GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| GB2460672B (en) | 2008-06-04 | 2012-01-04 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents |
| GB2471987B (en) * | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
| GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
-
2010
- 2010-03-12 GB GB1004137.4A patent/GB2478595B/en active Active
-
2011
- 2011-03-03 AR ARP110100670A patent/AR080454A1/es unknown
- 2011-03-09 TW TW100107897A patent/TWI461205B/zh not_active IP Right Cessation
- 2011-03-11 UA UAA201211775A patent/UA109271C2/uk unknown
- 2011-03-11 KR KR1020127026659A patent/KR20130067248A/ko not_active Ceased
- 2011-03-11 EP EP11709175.1A patent/EP2544682B1/en active Active
- 2011-03-11 MX MX2012010512A patent/MX2012010512A/es not_active Application Discontinuation
- 2011-03-11 HU HUE11709175A patent/HUE029817T2/en unknown
- 2011-03-11 AU AU2011225837A patent/AU2011225837A1/en not_active Abandoned
- 2011-03-11 CN CN2011800236521A patent/CN102869356A/zh active Pending
- 2011-03-11 ES ES11709175.1T patent/ES2569669T3/es active Active
- 2011-03-11 NZ NZ602953A patent/NZ602953A/en unknown
- 2011-03-11 CA CA2792722A patent/CA2792722A1/en not_active Abandoned
- 2011-03-11 US US13/634,343 patent/US8790719B2/en active Active
- 2011-03-11 NZ NZ629136A patent/NZ629136A/en unknown
- 2011-03-11 JP JP2012556592A patent/JP5785569B2/ja active Active
- 2011-03-11 DK DK11709175.1T patent/DK2544682T3/en active
- 2011-03-11 HR HRP20160427TT patent/HRP20160427T1/hr unknown
- 2011-03-11 PL PL11709175T patent/PL2544682T3/pl unknown
- 2011-03-11 EA EA201290901A patent/EA201290901A1/ru unknown
- 2011-03-11 SG SG2012067393A patent/SG184016A1/en unknown
- 2011-03-11 WO PCT/GB2011/050487 patent/WO2011110866A1/en not_active Ceased
- 2011-03-11 BR BR112012023017A patent/BR112012023017A8/pt not_active IP Right Cessation
- 2011-03-11 PH PH1/2012/501782A patent/PH12012501782A1/en unknown
- 2011-03-11 SI SI201130799A patent/SI2544682T1/sl unknown
-
2012
- 2012-09-10 IL IL221871A patent/IL221871A/en active IP Right Grant
- 2012-10-09 ZA ZA2012/07574A patent/ZA201207574B/en unknown
- 2012-10-09 CO CO12177686A patent/CO6630103A2/es unknown
-
2014
- 2014-04-24 US US14/260,876 patent/US9675654B2/en active Active
-
2016
- 2016-04-27 CY CY20161100356T patent/CY1117451T1/el unknown
- 2016-12-01 AU AU2016266059A patent/AU2016266059A1/en not_active Abandoned
-
2017
- 2017-06-12 US US15/620,435 patent/US20180042975A1/en not_active Abandoned
-
2018
- 2018-08-16 AU AU2018217273A patent/AU2018217273B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301340I2 (nl) | tisotumab vedotin | |
| NO2022039I1 (no) | Enfortumab vedotin | |
| PL2544682T3 (pl) | Fitokannabinoidy w leczeniu glejaka | |
| BR112012017441A2 (pt) | compostos e métodos | |
| EP2551283A4 (en) | ANTIALLERGENIC ACTIVE SUBSTANCE | |
| ME02952B (me) | Wnt antagonisti i metode tretiranja | |
| SMT201600050B (it) | Mezzi e metodi per trattare il dlbcl | |
| IT1400425B1 (it) | Modified snrnas for use in therapy. | |
| DK2552261T3 (da) | Propfilter med proprum med aromakugle | |
| HRP20160737T1 (hr) | Anti-her3-protutijela i njihove uporabe | |
| PT2552242E (pt) | Resumo | |
| DK2538984T3 (da) | Kompressionsforbinding | |
| DK2613884T3 (da) | Findelingsindretning | |
| LT2605789T (lt) | Modifikuoti relaksino polipeptidai ir jų panaudojimas | |
| DK3124610T3 (da) | Hbv-behandling | |
| EP2433335A4 (en) | Connector | |
| HRP20171579T8 (hr) | Antigljivična sredstva i njihova upotreba | |
| HRP20160922T1 (hr) | Oligopeptidni spojevi i njihove uporabe | |
| IL226427A0 (en) | Anti ccr4 antibodies and uses thereof | |
| PL2771037T3 (pl) | Środki terapeutyczne i ich zastosowania | |
| HRP20170936T1 (hr) | Alkilamido spojevi i njihova uporaba | |
| EP2872036A4 (en) | IN VIVO BIOSENSOR | |
| FR2963612B1 (fr) | Element en treillis et grue | |
| EP2613409A4 (en) | Connector | |
| EP2543712A4 (en) | IN COOLING MEDIUM |